Manish K. Jha, MD

Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas

JCP
Rapidity of Improvement With Intranasal Esketamine for MDD
Meta-Analysis

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.
Rebecca S. Hock, Anna Feeney, Nadia Iovieno, et al
JCP
Effect of Benzodiazepines on Antidepressant Effects of Ketamine
Original Research

November 14, 2022

Findings of studies examining the impact of benzodiazepines on antidepressant effects of ketamine are contradictory. This study assessed whether concomitant oral benzodiazepines differentially affected treatment response to ketamine versus...
Anna Feeney, Bettina B. Hoeppner, Marlene P. Freeman, et al
JCP
Meta-Analysis

June 15, 2021

Prior meta-analyses have found vortioxetine to be efficacious for depression. Building on those findings, the present meta-analysis examined the effect that placebo response has on drug-placebo effect size in...
Nadia Iovieno, George I. Papakostas, Anna Feeney, et al
JCP
Original Research

April 13, 2021

Is pain associated with irritability and depression? This study aimed to evaluate relationships between these symptom categories and determine how they may relate to functional impairments.
Manish K. Jha, Alan Schatzberg, Abu Minhajuddin, et al
JCP
Original Research

December 1, 2020

Adjunctive pimavanserin can reduce depressive symptoms and improve function in patients with major depression and inadequate antidepressant response. This analysis evaluated the effects of adjunctive pimavanserin on sleep/wakefulness disturbances.
Manish K. Jha, Maurizio Fava, Marlene P. Freeman, et al
JCP
Original Research

August 11, 2020

An antidepressant medication switch often follows a failed initial trial with SSRIs. This study sought to determine the probability and timing of both response and remission and the optimal...
A. John Rush, Charles South, Manish K. Jha, et al
JCP
Meta-Analysis

May 26, 2020

The FDA has now approved intranasal esketamine as augmention in treatment-resistant depression, and recent studies of its efficacy have been encouraging. This meta-analysis synthesizes the evidence to provide an...
George I. Papakostas, Naji C. Salloum, Rebecca S. Hock, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe